A multicenter phase 3 clinical trial is being conducted to study the efficacy and safety of a clinical trial drug (Romosozumab) compared to bisphosphonates in children and adolescents who have OI.  The trial is open to eligible children from age 5 to less than 18 years of age who have diagnoses of OI Type I, III, or IV. The clinical trial will have sites participating in the following countries: United States, Australia, Austria, Belgium, Canada, China, France, Germany, Hungary, Japan, Poland, Slovakia, Spain, Switzerland, Turkey (Türkiye), United Kingdom.

For more information, please visit the clinical trial registry page at https://app.patientwing.com/campaign/OIF.